Effects of Arsenic Trioxide Alone and in Combination with Bortezomib in Multiple Myeloma RPMI 8266 Cells

  • Elmahi, Aadil Yousif (Cancer Center, the First Hospital of Jilin University) ;
  • Niu, Chao (Cancer Center, the First Hospital of Jilin University) ;
  • Li, Wei (Cancer Center, the First Hospital of Jilin University) ;
  • Li, Dan (Cancer Center, the First Hospital of Jilin University) ;
  • Wang, Guan-Jun (Cancer Center, the First Hospital of Jilin University) ;
  • Hao, Shan-Shan (Cancer Center, the First Hospital of Jilin University) ;
  • Cui, Jiu-Wei (Cancer Center, the First Hospital of Jilin University)
  • Published : 2013.11.30


The aim of this study was to detect the efficiency of arsenic trioxide (ATO) alone or together with bortezomib to inhibit proliferation and induce apoptosis in a multiple myeloma (MM) RPMI 8266 cells. Mechanisms of action were also investigated. RPMI 8266 cells were treated with ATO alone and in combination with bortezomib for 24 hours, and cell viability was assessed by modified MTT. Annexin V-F1TC and PI staining was used to detect the apoptosis rate and cell cycling was investigated by flow cytometry, along with expression of cell surface death receptor-4(DR4) and death receptor-5 (DR5). Western blotting was applied to detect the expression of bcl-2, caspase-3, caspase-8, and caspase-9. As a result, the ATO combined with bortezomib group showed more inhibition of RPMI 8266 cell viability than theATO group. Expression of DR4 and DR5 on the cell surfaces, and the apoptosis rate were increased after treatment by ATO alone or combined with bortezomib. The cells appeared to arrest in G2/M phase after treatment. Expression of bcl-2 was more significantly decreased in the combination group, and that of caspase-3, caspase-8 and caspase-9 was significantly increased as well. Therefore, bortezomib can enhance ATO actions to induce apoptosis in RPMI 8266 cells, with decrease in expression of bcl-2 and increase of caspase-3, caspase-8 and caspase-9 proteins.


Arsenic trioxide;bortezomib;multiple myeloma;apoptosis


  1. Badros AZ, Goloubeva O, Rapoport AP, et al (2005). Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol, 23, 4089-99.
  2. Canestraro M, Galimberti S, Savli H, et al (2010). Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet, 199, 110-20.
  3. Gupta S, Yel L, Kim D, et al (2003). Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther, 2, 711-9.
  4. Hou J, Xiong H, Gao W, and Jiang H (2005). 2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk Res, 29, 1059-67.
  5. Johnstone RW, Ruefli AA, and Lowe SW (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108, 153-64.
  6. Morales AA, Gutman D, Lee KP, and Boise LH (2008). BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood, 111, 5152-62.
  7. Mousa SA, O’Connor L, Rossman TG, and Block E (2007). Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis, 28, 962-7.
  8. Palumbo A, and Anderson K (2011). Multiple myeloma. N Engl J Med, 364, 1046-60.
  9. Sanaat Z, Rezazadeh M, Gharamaleki JV, et al (2011). Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran, 49, 504-8.
  10. Tardy C, Codogno P, Autefage H, et al (2006). Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). Biochim Biophys Acta, 1765, 101-25.
  11. Wang MM, Dou HJ, Zou LF, et al (2008). [Correlation of cell cycle alteration to SOCS-1 gene demethylation induced by arsenic trioxide in myeloma cell lines]. Ai Zheng, 27, 1150-4.
  12. Yedjou C, Tchounwou P, Jenkins J, and McMurray R (2010). Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol, 3, 28.

Cited by

  1. Arsenic Trioxide Inhibits Cell Growth and Invasion via Down-Regulation of Skp2 in Pancreatic Cancer Cells vol.16, pp.9, 2015,